NYSE:Ultragenyx Pharmaceutical Inc.

График котировок Ultragenyx Pharmaceutical Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 37.52
P/BV 13.55
EV/EBITDA -38.61
EBITDA -0.32
Цена ао 142.76

Инсайдерская торговля

Дата сделки Дата раскрытия Инсайдер Тип Цена Объем Количество Доля до, % Доля после, % Документ
07.01.2021 08.01.2021 Huizenga Theodore Alan
SVP, Controller and PAO
Продажа 140.65 562 600.00 4000 0 -0.01 ссылка
07.01.2021 08.01.2021 Huizenga Theodore Alan
SVP, Controller and PAO
Покупка 21 84 000.00 4000 0 0.01 ссылка

Основные владельцы

Institutions Объем Доля, %
First Trust Portfolios L.P. 17441 0.03
Global X Management Company LLC 59707 0.09
Federated Equity Mgmt Co. Of Penn 3997800 6.04
Delaware Management Company 2025776 3.06
Security Investors, LLC 81165 0.12
Boston Company Asset Mgmt, LLC 41476 0.06
GO ETF Solutions LLP 11491 0.02
Equitable 456565 0.69
Operadora Actinver SA de CV 22600 0.03
Federated Hermes, Inc. 2053812 3.1
Legg Mason Partners Fund Advisor, LLC 1692090 2.56
Capital Research and Management Company 22248760 33.63
BlackRock Fund Advisors 2790882 4.22
Danske Bank Asset Management 48725 0.07
Riedweg & Hrovat AG 29900 0.05
Advisors Asset Management, Inc. 200 0
PMG Fonds Management AG 22000 0.03
Northern Trust Investments Inc 1112279 1.68
APS Labs, LLC 2441 0
T. Rowe Price 1073383 1.62
ClearBridge Investments, LLC. 982886 1.49
Zeus Asset Management S.A. 1254 0
Riedweg & Hrovat AG 29900 0.05
Deutsche Asset Management Investment GmbH 156502 0.24

Содержится в ETF

ETF Доля, % Доходность за год, %
iShares Russell 2000 ETF 0.34 29.11
Vanguard Russell 2000 ETF 0.32 29.44
First Trust Amex Biotechnology Index 4.55 13.52
John Hancock Multifactor Small Cap ETF 0.59 16.49
Vanguard Russell 2000 Growth ETF 0.62 41.51
ProShares UltraPro Russell2000 0.19 10.48
ProShares Ultra Russell2000 0.21 31.99
Motley Fool Small-Cap Growth ETF 4.72
Global X Genomics & Biotechnology ETF 4.39 59.03
ProShares Hedge Replication 0.07 9.30
iShares Russell 2000 Growth ETF 0.65 42.68
Global X Founder-Run Companies ETF 1.26 49.60
iShares Morningstar Small-Cap Growth ETF 0.93 49.87

Похожие компании

Описание Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.